Elana Frankel had retreated to bed rest for a year, having been shocked out of modern life with a traumatic brain injury. "After I finished a round of anti-seizure medications, there weren't any other pharmaceuticals available to help me with my brain injury," Frankel said. "All of the neurosurgeons [who] I consulted said I needed bed rest until the inflammation goes down."

Learn More

Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles.

Learn More

Giving a definition of the complex endogenous signaling system known as the "endocannabinoid system" is becoming an increasingly difficult task. In fact, the number of potential components of this system, which was originally identified from studies on the mechanism of action of the psychotropic ingredient of some varieties of cannabis.

Learn More

Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a "high." A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia.

Learn More

Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD’s potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies.

Learn More

Cannabidiol (CBD) is one of the main pharmacologically active phytocannabinoids of Cannabis sativa L. CBD is non-psychoactive but exerts a number of beneficial pharmacological effects, including anti-inflammatory and antioxidant properties. The chemistry and pharmacology of CBD, as well as various molecular targets, including cannabinoid receptors and other components of the endocannabinoid system with which it interacts, have been extensively studied.

Learn More

Disclaimer: O Bon Living did not write, participate, or corroborate with the information contained in the provided references. Any claims are solely the responsibility of the original authors of the work. As research into cannabinoids progresses, O Bon Living will continue to update this list to provide you with the new insights in the field.